Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning

Davda, Sonal; Bezabeh, Tedros

doi:10.1007/s10555-006-9009-z

Cited by 36 publications

(64 citation statements)

References 91 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assessing hypoxia using endogenous molecular markers would be a cost effective approach that could be used by oncologists worldwide (Le et al, 2007). Endogenous molecular markers need not additional invasive procedure beyond that of a tumor biopsy at diagnosis (Davda and Bezabeh, 2006). However, single endogenous molecular markers can be influenced by factors other than hypoxia.…”

Section: Discussionmentioning

confidence: 99%

Expression of Endogenous Hypoxia Markers in Vulvar Squamous Cell Carcinoma

Li²,

Li³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To investigate the expression of endogenous hypoxia-related markers identified as being involved in vulvar squamous cell carcinoma (VSCC). Methods: We performed immunohistochemical staining of hypoxia-inducible factor-1α (HIF-1α), glucose transporter-1 (GLUT-1), carbonic anhydrase 9 (CA-9) and vascular endothelial growth factor (VEGF), on tissue sections of 25 VSCC patients, 10 vulvar intraepithelial neoplasia (VIN) patients and 12 healthy controls. Results: HIF-1α expression was found in all sections, with no significant difference between controls, VIN and VSCC sections (all P<0.05). Glut-1 expression was found in 25% of control, 90% of VIN and 100% of VSCC sections. A significant difference between control and VIN or VSCC was observed (all P<0.05), while no difference was found between VIN and VSCC sections (P>0.05). CA-9 expression was negative in control sections, but it was found in 30% of VIN sections and 52% of VSCC sections with strong staining. Similarly, CA-9 expression also showed obvious differences between controls and VIN or VSCC sections (all P<0.05). However, there was no significant difference between VIN and VSCC (P>0.05). There were only 25% of control sections with weak VEGF expression, while strong staining was found in about 60% of VIN sections and 25% of VSCC sections (all P<0.05). In addition, a difference was also found between VIN and VSCC sections (P<0.05). Conclusion: Expression of endogenous hypoxia markers (HIF-1α, GLUT-1, CA-9 and VEGF) might be involved in the malignant progression of VSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Endogenous Hypoxia Markers in Vulvar Squamous Cell Carcinoma

Li²,

Li³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The oxygen concentration relevant for identifying radioresistant hypoxic cells (1% oxygen volume or *7 mmHg of partial oxygen pressure) (5,40,111) is sufficient to drive the uptake of 2-nitroimidazoles and Cu-chelated complexes into hypoxic tissues, making them relevant markers for assessing hypoxia. The differential uptake and washout between hypoxic and normoxic cells provides a selective demarcation of hypoxic cells in vivo (56). PET-based biomarker provides composite oxygenation information on tumors, and repeated measurements are possible.…”

Section: The Clinical Importance Of Assessing Tumor Hypoxiamentioning

confidence: 99%

The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities

Walsh

Lebedev

Aten³

et al. 2014

Antioxidants & Redox Signaling

344

317

View full text Add to dashboard Cite

Tumor hypoxia is a well-established biological phenomenon that affects the curability of solid tumors, regardless of treatment modality. Especially for head and neck cancer patients, tumor hypoxia is linked to poor patient outcomes. Given the biological problems associated with tumor hypoxia, the goal for clinicians has been to identify moderately to severely hypoxic tumors for differential treatment strategies. The ''gold standard'' for detecting and characterizing of tumor hypoxia are the invasive polarographic electrodes. Several less invasive hypoxia assessment techniques have also shown promise for hypoxia assessment. The widespread incorporation of hypoxia information in clinical tumor assessment is severely impeded by several factors, including regulatory hurdles and unclear correlation with potential treatment decisions. There is now an acute need for approved diagnostic technologies for determining the hypoxia status of cancer lesions, as it would enable clinical development of personalized, hypoxia-based therapies, which will ultimately improve outcomes. A number of different techniques for assessing tumor hypoxia have evolved to replace polarographic pO 2 measurements for assessing tumor hypoxia. Several of these modalities, either individually or in combination with other imaging techniques, provide functional and physiological information of tumor hypoxia that can significantly improve the course of treatment. The assessment of tumor hypoxia will be valuable to radiation oncologists, surgeons, and biotechnology and pharmaceutical companies who are engaged in developing hypoxia-based therapies or treatment strategies. Antioxid. Redox Signal. 21, 1516-1554.

show abstract

“…Tumor control probability models based on repeated [ 288,289 . 290 . Therefore, instead of using bioreductive exogenous drugs, our laboratory is investigating the possibility of imaging the endogenous marker carbonic anhydrase (CA) IX.…”

Section: Imaging Acute and Chronic Tumor Hypoxiamentioning

confidence: 99%